Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun:131:119-126.
doi: 10.1016/j.ijid.2023.03.036. Epub 2023 Mar 23.

Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montréal, Canada

Affiliations

Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montréal, Canada

Kate Zinszer et al. Int J Infect Dis. 2023 Jun.

Abstract

Objectives: To use serological testing to assess the pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies in children and adolescents in Montréal, Canada.

Design: This analysis is from a prospective cohort study of children aged 2-17 years (at baseline) that included blood spots for antibody detection. The serostatus of participants was determined by enzyme-linked immunosorbent assays using the receptor-binding domain from the spike protein and the nucleocapsid protein as antigens. We estimated seroprevalence, seroconversion rates, and the likelihood of seroreversion at 6 months and 1 year.

Results: The baseline (October 2020 to April 2021) seroprevalence was 5.8% (95% confidence interval [CI] 4.8-7.1), which increased to 10.5% (May to September 2021) and 11.0% (November 2021 to March 2022) for the respective follow-ups (95% CI 8.6-12.7; 95% CI 8.8-13.5). The crude rate of seroconversion over the study period was 12.8 per 100 person-years (95% CI 11.0-14.7). The adjusted hazard rates of seroconversion by child characteristics showed higher rates in children who were female, whose parent identified as a racial or ethnic minority, and in households with incomes in the lowest tercile of our study population. The likelihood of remaining seropositive at 6 months was 68% (95% CI 60-77%) and dropped to 42% (95% CI 32-56%) at 1 year.

Conclusion: Serological studies continue to provide valuable contributions for infection prevalence estimates and help us better understand the dynamics of antibody levels after infection.

Keywords: Cohort; Pediatric; SARS-CoV-2; Seroconversion; Serology; Seroreversion.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curve of time to seroreversion in the sample of unvaccinated children and vaccinated children censored at vaccination. In the upper figure, the darker gray line represents the estimated likelihood of remaining seropositive to at least that time point, with the light gray representing the 95% confidence intervals. The lower figure represents the number of seropositive children that remain at risk of seroreversion at five points in time.

References

    1. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–848. doi: 10.1038/s41591-020-0897-1. - DOI - PubMed
    1. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5 doi: 10.1126/sciimmunol.abe5511. - DOI - PMC - PubMed
    1. Poehlein E, Rane MS, Frogel D, Kulkarni S, Gainus C, Profeta A, et al. Presence of SARS-CoV-2 antibodies following COVID-19 diagnosis: a longitudinal study of patients at a major urgent care provider in New York. Diagn Microbiol Infect Dis. 2022;103 doi: 10.1016/j.diagmicrobio.2022.115720. - DOI - PMC - PubMed
    1. COVID-19 Community Research Partnership Study Group Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership. BMC Infect Dis. 2021;21:889. doi: 10.1186/s12879-021-06517-6. - DOI - PMC - PubMed
    1. Di Chiara CD, Cantarutti A, Costenaro P, Donà D, Bonfante F, Cosma C, et al. Long-term immune response to SARS-CoV-2 infection among children and adults after mild infection. JAMA Netw Open. 2022;5 doi: 10.1001/jamanetworkopen.2022.21616. - DOI - PMC - PubMed

Substances